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The problem 
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical 
practice.(1) AF conveys significant health risks, most notably from a 5-fold increased risk of 
stroke.(2) Strokes attributable to AF are of a greater severity, cause greater disability and 
mortality, and result in greater healthcare costs than non-AF related strokes.(3)  
 
Around 40% of people with AF are asymptomatic and are described as having ‘silent’ AF.(4) It 
is therefore unsurprising that over 12% of people are found to have AF at the first 
presentation of a stroke. Early identification and treatment of AF before the occurrence of 
stroke is, therefore, of paramount importance to improve population health.  
 
AF screening has been recommended but is yet to be implemented. Recommendations 
currently suggest screening in patients 65 years of age(5) but the yield of interventions for 
detecting new AF varies considerably according to the age of populations screened and 
interventions tested.(6) Identifying those at high risk of developing new AF, including those 
with “silent AF”, would enable better targeting  of screening interventions and consequently 
has the potential to improve the effectiveness and cost-effectiveness of future AF screening 
programmes. 
 
Predicting the risk of developing AF 
A variety of clinical, electrocardiographic (ECG) and biochemical markers have been identified 
as risk factors for the development of new AF. From these risk factors a number of risk 
prediction models have been developed (Table 1). Whilst all studies have utilised large patient 
datasets to derive and validate risk prediction models, only some have been developed using 
unselected primary care populations and all have been developed in non-UK populations.   
 
Limitations of risk prediction models for new AF 
Existing models only have moderate abilities to predict new AF and do not evaluate the 
incremental effects of different risk predictors for AF. Furthermore, risk models 
predominately use clinical characteristics to predict the occurrence of new AF and, of those 
that use ECG parameters, only a few ECG markers have been utilised. No models have 
incorporated biochemical markers for AF risk prediction. There remains an opportunity to 
improve the predictive abilities and risk stratification against AF outcomes by combining 
clinical, ECG and biochemical parameters. 
  
Research suggests that existing risk prediction models may not be transferrable across 
populations. The US derived CHARGE-AF prediction tool was applied to the UK EPIC Norfolk 
cohort (n=24,020). Although CHARGE-AF was found to have reasonable discrimination (C-
statistic (95% CI) 0.81 (0.75-0.85) there was weak calibration of this model with a nearly 2-
fold overestimation of AF incidence.(7) Therefore an important consideration for future 
research would be to develop and validate prediction models using data from the target 
population.   
    
Existing risk prediction models have been developed using epidemiological methods which 
can be improved upon using newer techniques, such as “artificial intelligence” or “machine 
learning”. Previous approaches to developing risk prediction models rely on statistical 
modelling of ‘survival rates’ associated with patient baseline characteristics. These methods 
assume linearity in relationships between individual characteristics on outcomes (e.g. the 
relationship between increasing age and developing new AF is linear) and linearity in the 
effect of multiple characteristics on outcomes (e.g. the increased risk of developing AF from 
the combined effects of hypertension and increased age is linear). These assumptions may be 
inaccurate and novel approaches to determining risk prediction, such as artificial intelligence 
technology, may overcome such limitations.  
 
The role of Artificial Intelligence (AI) technology  
Machine learning is computer-based learning using  artificial intelligence technology to derive 
and enable pattern recognition within routinely collected clinical data.(9, 10) Machine learning 
could be used to better analyse integrated healthcare datasets for the derivation of better 
clinical evidence as it can overcome the assumptions of linearity when modelling multiple 
interacting risk factors. Machine learning was recently found to improve the accuracy of 
predicting all-cause mortality than conventional risk factor modelling in a prospective cohort 
of patients (n=502,628) from UK-Biobank.(8) Moreover, machine learning enables pattern 
recognition within data with a potential to identify new risk factors for disease that may 
previously have been unrecognised. 
 
Potential for research 
With the rapid emergence of artificial intelligence technology, researchers are increasingly  
questioning if there is an opportunity to improve the methodological interrogation of 
routinely collected patient data to improve healthcare outcomes. With regards to AF, should 
researchers be considering who may develop AF in the future to enable better targeting of AF 
detection interventions?  There is now an opportunity to use technological advances to 
identify new risk factors for AF within large patient datasets and to develop tools for 
predicting those at greatest risk of developing AF. Indeed, primary care systems currently 
have risk prediction tools embedded within clinical systems (e.g. Q-Risk) so translation of such 
research into clinical practice is no longer a barrier. 
 
  
Table 1: Studies of risk prediction models for the development of new AF 
Study Country Design and 
sample size 
Risk predictors used in 
model 
Prediction 
time 
Predictive 
ability using 
C-Statistic* or 
Hazard 
Ratio** (95% 
CI) 
Alonso 2013 United 
States 
CHARGE-AF 
Cohort  
(3 
amalgamated 
cohorts for 
derivation; 
external 
validation in 
AGES and 
Rotterdam 
study cohorts) 
 
N = 18,556 
(derivation) 
N = 7,672 
(validation) 
Clinical: 
Age, Race, Height, 
Weight, BP, treatment 
for hypertension, 
smoking, diabetes, 
previous MI, heart 
failure 
 
ECG: 
PR interval, LVH 
5 years AGES:  
*0.66  
(0.63-0.70) 
 
Rotterdam: 
*0.71 
(0.66-0.75) 
Saliba 2016 Israel Retrospective 
analysis of 
national 
healthcare 
database 
 
N = 1,062,073  
Clinical: 
CHADS2 (Congestive 
heart failure, 
hypertension, Age>75, 
diabetes, stroke) 
 
CHA2DS2VASc 
(Congestive heart 
failure, hypertension, 
Age>75, diabetes, 
stroke, vascular 
disease, Age>65, sex 
category) 
2 years CHADS2: 
*0.73 
(0.73-0.74) 
 
CHA2DS2VASc: 
*0.74  
(0.74-0.75) 
Schnabel 
2009 
United 
States 
Cohort 
(Framingham 
Heart Study) 
 
N = 4,764 
Clinical: 
Age, Sex, BMI, SBP, 
treatment for 
hypertension, cardiac 
murmur, heart failure 
 
ECG: 
PR interval 
5 years *0.78  
(0.76-.080) 
Chamberlain 
2011 
United 
States 
ARIC Cohort 
study 
Cohort study 
of Black 
population 
 
N = 14.546  
Clinical: 
Age, Race, Height, SBP, 
treatment for 
hypertension, smoking, 
cardiac murmur,  
diabetes, IHD, heart 
failure 
1 year *0.78  
(95% CI not 
reported) 
 
ECG: 
LVH 
Cabrera 
2016 
Spain Cross-
sectional 
analysis of 
Holter 
monitor 
results 
 
N = 299 
Clinical:  
Age, heart 
failure/cardiomyopathy 
 
ECG: 
PAC>=0.2%; PR interval 
2 years *0.79  
(0.71-0.88) 
Brunner 
2014 
United 
states 
Retrospective 
analysis of 
outpatient 
medical 
records 
database 
 
N = 100,000 
Clinical:  
Age, IHD, diabetes, sex, 
heart failure, 
hypertension, valvular 
disease 
5 years *0.81  
(0.81-0.82) 
Suenari 2017 Taiwan Retrospective 
analysis of 
national 
health 
insurance 
database 
(HATCH 
score) 
 
N = 670,804 
Clinical: 
hypertension, age >75 
years, stroke or TIA, 
COPD, heart failure 
2 years **2.06  
(2.03-2.09) for 
each 1 point 
increment in 
score 
ECG: Electrocardiogram; BMI = Body Mass Index; BP = blood pressure, SBP = systolic blood 
pressure; MI = Myocardial infarction; LVH = Left Ventricular Hypertrophy; IHD = ischaemic 
heart disease; PAC = premature atrial complexes; TIA = Transient Ischaemic Attack; COPD = 
Chronic Obstructive Pulmonary Disease.  
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